Similar articles

• Increased activity of enzymes for de novo pyrimidine biosynthesis after orotic acid administration.

  Bresnick E, Mayfield ED Jr, Mossé H. Bresnick E, et al. Mol Pharmacol. 1968 Mar;4(2):173-80. Mol Pharmacol. 1968. PMID: 5645613 No abstract available.
• Pharmacology of 3,5-diamino-1,24-triazole (guanazole). 1. Antitumor activity of guanazole.

  Hahn MA, Adamson RH. Hahn MA, et al. J Natl Cancer Inst. 1972 Mar;48(3):783-90. J Natl Cancer Inst. 1972. PMID: 4621741 No abstract available.
• Use of mouse vaginal and rectal epithelium to screen antimitotic effects of systemically administered drugs.

  Bonder RH, Van Scott EJ. Bonder RH, et al. Cancer Res. 1971 Jun;31(6):851-3. Cancer Res. 1971. PMID: 5088490 No abstract available.
• Selective suppression of humoral immunity by antineoplastic drugs.

  Heppner GH, Calabresi P. Heppner GH, et al. Annu Rev Pharmacol Toxicol. 1976;16:367-79. doi: 10.1146/annurev.pa.16.040176.002055. Annu Rev Pharmacol Toxicol. 1976. PMID: 779618 Review. No abstract available.
• Antineoplastic drugs: clinical pharmacology and therapeutic use.

  Bender RA, Zwelling LA, Doroshow JH, Locker GY, Hande KR, Murinson DS, Cohen M, Myers CE, Chabner BA. Bender RA, et al. Drugs. 1978 Jul;16(1):46-87. doi: 10.2165/00003495-197816010-00003. Drugs. 1978. PMID: 78795 Review. No abstract available.